Nine Men Reverse Epigenetic Age by 2.5 Years in Clinical Trial

Nine men reverse epigenetic age by 2.5 years

Can aging be measured with a chemical clock and reversed? A clinical trial published in September 2019 in the journal Aging Cell suggests yes. The study, named TRIIM and authored by Gregory M. Fahy, Robert T. Brooke, Steve Horvath, and other researchers, applied a protocol for one year involving growth hormone, metformin, and a third diabetes drug to nine healthy men aged 51 to 65. The declared goal was not to halt aging, but to regenerate the thymus. The results, according to the authors, were different: four distinct epigenetic clocks detected an average reversal of biological age of about 2.5 years.

The sample is tiny. Two cohorts, seven men first and three later, recruited via advertisements and without a control group. The authors themselves acknowledge at the end of the text that several researchers have conflicts of interest. With these caveats, the finding is suggestive, not conclusive.

What the TRIIM study measures exactly

The trial does not measure wrinkles or gray hair. It measures epigenetic clocks: estimators based on DNA methylation patterns that assign a biological age to cells. Four of them agreed that the participants' epigenetic age decreased after twelve months of treatment. The average change was approximately 2.5 years.

The effect, according to the text, did not depend on the starting age or baseline epigenetic age. The authors describe it as «robust evidence» that the regression of multiple aging biomarkers is possible in humans. They also detected immunological changes: a decrease in total monocytes and CD38+ monocytes, and an increase in the lymphocyte/monocyte ratio. The correlation between the reversal and this reduction of CD38+ monocytes was statistically significant.

The protocol sought to regenerate the thymus, an organ that atrophies with age. Growth hormone had already shown this capacity in rats and dogs, according to the review accompanying the trial. The surprise was finding, by the way, signals of reversal in other markers.

Growth hormone, metformin, and a third drug

The cocktail combines three pieces. The growth hormone stimulates thymus regeneration. Metformin, a classic antidiabetic, improves insulin sensitivity and reduces blood glucose. The third drug, also for diabetes, completes the scheme.

Metformin is cheap and accessible. It is sold in pharmacies for about two euros per package, although it requires a prescription. Its side effects are known and not trivial: diarrhea, bloating, stomach pain, flatulence, metallic taste, headache. The FDA lists them. Anyone thinking of self-medicating with it should read that list first.

Growth hormone is something else. It is expensive, injectable, and its use off-label carries risks. In the bodybuilding circuit, cheaper alternatives circulate, such as MK-677, a ghrelin agonist that stimulates endogenous growth hormone production. It causes fierce hunger, to the point of preventing sleep if taken at night. It is not approved for human use.

Intermittent fasting: the shortcut that needs no prescription

If the mechanism involves lowering insulin and raising growth hormone, there is a free path. Intermittent fasting reduces blood insulin levels, especially after sixteen hours, and elevates growth hormone. This facilitates fat burning and, according to popular literature, improves the immune system and regenerates joints.

Cutting refined carbohydrates and approaching a ketogenic diet aims at the same goal through another door. The uncomfortable economic question is: what is better for the industry, recommending fasts or prescribing pills? Metformin costs pennies, but the rest of the protocol does not.

There is a nuance that should not be lost. Fasting and low-carb diets also have costs: they can weaken hair and, if poorly planned, age instead of rejuvenate. There is no free food, even when you stop eating.

The limits: small sample, no control, and conflicts

The study has nine participants. There is no control group. The probability that part of the result is due to chance is high. The authors themselves call for replication with larger samples. Several researchers declare conflicts of interest at the end of the paper.

None of this turns the trial into a sham. It is normal in early phases: it is tested with few subjects, and if it looks promising, investment in better studies trinc. But one should not confuse a signal with a conclusion.

What if it works? The price is decided by the market. Growth hormone is not cheap. Metformin is. A combined treatment for years would be within reach of those who can afford it, not everyone. Longevity, like almost everything, has a bill.

Reasonable skepticism

Two and a half years of epigenetic reversal are not seen in the mirror. A person with two more or fewer years looks practically the same outside. One can «rejuvenate» more by exercising, sleeping well, and eating decently. The difference is that this does not sell headlines.

The advertisement looks like the habitable planets we will never reach. It is promising, it is real in the lab, and it is far from changing anyone's life. When rejuvenation is measured in lustres and not months, the conversation will be different.

Meanwhile, the business is already set up. There are clinics, supplements, and protocols that promise what the paper only hints at. Science advances slowly. Marketing does not.